Skip to main content
Erschienen in: Tumor Biology 1/2012

01.02.2012 | Research Article

Activation of AKT is associated with metastasis of nasopharyngeal carcinoma

verfasst von: Ying Liu, Long-Hua Chen, Ya-Wei Yuan, Qi-Sheng Li, Ai-Ming Sun, Jian Guan

Erschienen in: Tumor Biology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Although radiotherapy results of nasopharyngeal carcinoma (NPC) at an early stage are better than other tumors, there is still a portion of patients with NPC who die before 5 years after the treatment; the underlying mechanism remains to be further understood. This study aims to investigate the mechanism by which NPC cells escape from irradiation. Patients with NPC at stage I was included in this study. All the patients were treated with irradiation. NPC biopsies were obtained from each patient before and 1 week after the start of radiotherapy. Expression of AKT in NPC tissue was assessed by Western blotting. NPC cell line, SUNE-1 cells, was treated with irradiation. The levels of AKT in SUNE-1 cells were also assessed. The frequency of apoptotic SUNE-1 cells was evaluated by flow cytometry. The levels of AKT were markedly increased in NPC tissue after treatment with irradiation, which was significantly correlated with NPC metastasis and mortality. After irradiation, NPC cell line, SUNE-1 cells, expressed higher levels of AKT than control cells. The knockdown of AKT in SUNE-1 cells markedly increased apoptotic cell rate. Radiotherapy can increase the levels of AKT in NPC cells that are associated with NPC metastasis and increase in mortality.
Literatur
1.
Zurück zum Zitat Marcus KJ, Tishler RB. Head and neck carcinomas across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:52–7.PubMedCrossRef Marcus KJ, Tishler RB. Head and neck carcinomas across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:52–7.PubMedCrossRef
2.
Zurück zum Zitat Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol. 2008;44:617–27.PubMedCrossRef Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol. 2008;44:617–27.PubMedCrossRef
3.
Zurück zum Zitat Sterzing F, Stoiber E, Nill S, Bauer H, Huber P, Debus J, et al. Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents—a single institution’s experience and a review of the literature. Radiat Oncol. 2009;4:37.PubMedCrossRef Sterzing F, Stoiber E, Nill S, Bauer H, Huber P, Debus J, et al. Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents—a single institution’s experience and a review of the literature. Radiat Oncol. 2009;4:37.PubMedCrossRef
4.
Zurück zum Zitat Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am. 2008;22:1267–78.PubMedCrossRef Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am. 2008;22:1267–78.PubMedCrossRef
5.
Zurück zum Zitat Koon HK, Chan PS, Wong RN-S, Wu ZG, Lung ML, Chang CK, et al. Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem. 2009;108:1356–63.PubMedCrossRef Koon HK, Chan PS, Wong RN-S, Wu ZG, Lung ML, Chang CK, et al. Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem. 2009;108:1356–63.PubMedCrossRef
6.
Zurück zum Zitat Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets. 2011;15(1):63–74.PubMedCrossRef Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets. 2011;15(1):63–74.PubMedCrossRef
7.
Zurück zum Zitat Ming M, He YY. PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol. 2009;129:2109–12.PubMedCrossRef Ming M, He YY. PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol. 2009;129:2109–12.PubMedCrossRef
8.
Zurück zum Zitat Kfir-Erenfeld S, Sionov RV, Spokoini R, Cohen O, Yefenof E. Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leuk Lymphoma. 2010;51:1968–2005.PubMedCrossRef Kfir-Erenfeld S, Sionov RV, Spokoini R, Cohen O, Yefenof E. Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leuk Lymphoma. 2010;51:1968–2005.PubMedCrossRef
9.
Zurück zum Zitat Castaneda C, Cortes-Funes H, Gomez H, Ciruelos E. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Meta Rev. 2010;29:751–9.CrossRef Castaneda C, Cortes-Funes H, Gomez H, Ciruelos E. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Meta Rev. 2010;29:751–9.CrossRef
10.
Zurück zum Zitat Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways1. Radiat Res. 2003;159:283–300.PubMedCrossRef Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways1. Radiat Res. 2003;159:283–300.PubMedCrossRef
11.
Zurück zum Zitat Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008;9:288–96.PubMedCrossRef Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008;9:288–96.PubMedCrossRef
12.
Zurück zum Zitat Eke I, Koch U, Hehlgans S, Sandfort V, Stanchi F, Zips D, et al. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1[alpha]. (Research article)(Report). J Clin Invest. 2010;120:2516–27.PubMedCrossRef Eke I, Koch U, Hehlgans S, Sandfort V, Stanchi F, Zips D, et al. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1[alpha]. (Research article)(Report). J Clin Invest. 2010;120:2516–27.PubMedCrossRef
13.
Zurück zum Zitat Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003;4:13–21.PubMedCrossRef Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003;4:13–21.PubMedCrossRef
14.
Zurück zum Zitat Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–80.PubMedCrossRef Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–80.PubMedCrossRef
15.
Zurück zum Zitat Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010;19:919–30.PubMedCrossRef Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010;19:919–30.PubMedCrossRef
16.
Zurück zum Zitat Jamil N, Howie S, Salter DM. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol. 2010;91:387–93.PubMedCrossRef Jamil N, Howie S, Salter DM. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol. 2010;91:387–93.PubMedCrossRef
17.
Zurück zum Zitat Vens C, Begg AC. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin Radiat Oncol. 2010;20:241–9.PubMedCrossRef Vens C, Begg AC. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin Radiat Oncol. 2010;20:241–9.PubMedCrossRef
18.
Zurück zum Zitat Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Societ Nephrol. 2010;5:1312–29.CrossRef Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Societ Nephrol. 2010;5:1312–29.CrossRef
19.
Zurück zum Zitat Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.PubMedCrossRef Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.PubMedCrossRef
20.
Zurück zum Zitat Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.PubMedCrossRef Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71.PubMedCrossRef
Metadaten
Titel
Activation of AKT is associated with metastasis of nasopharyngeal carcinoma
verfasst von
Ying Liu
Long-Hua Chen
Ya-Wei Yuan
Qi-Sheng Li
Ai-Ming Sun
Jian Guan
Publikationsdatum
01.02.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0272-4

Weitere Artikel der Ausgabe 1/2012

Tumor Biology 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.